Liminatus Pharma (LIMN) Invested Capital (2024 - 2026)

Liminatus Pharma has reported Invested Capital for 3 years, with the latest figure at $1.4 million in Q1 2026.

• Quarterly Invested Capital rose 596.86% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (down 77.62% YoY) and the FY2025 annual result came in at $1.4 million, down 92.78% from the prior year.
• Invested Capital held at $1.4 million in Q1 2026 per LIMN's latest filing, from $1.4 million in the prior quarter.
• Over five years, Invested Capital peaked at $20.0 million in Q4 2024 and troughed at $207000.0 in Q1 2025.
• A 3-year average of $3.9 million and a median of $1.4 million in 2025 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2025 and 2026: Invested Capital tumbled 92.78% in 2025, then soared 596.86% in 2026.
• Over 3 years, Invested Capital stood at $20.0 million in 2024, then sank by 92.78% to $1.4 million in 2025, then changed by 0.0% to $1.4 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $1.4 million, $1.4 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.